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Pulmonary Arterial Thrombosis in Eisenmenger
Syndrome Is Associated With Biventricular
Dysfunction and Decreased Pulmonary Flow Velocity
Craig S. Broberg, MD,*† Masuo Ujita, MD,‡ Sanjay Prasad, MD,§ Wei Li, MD, PHD,*
Michael Rubens, FRCR,‡ Bridget E. Bax, PHD, Simon J. Davidson, FIBMS, CSCI,¶
Beatriz Bouzas, MD,* J. Simon R. Gibbs, MD,# John Burman, MD,¶
Michael A. Gatzoulis, MD, PHD*
London, England; and Portland, Oregon
Objectives This study sought to determine what factors are associated with pulmonary artery thrombi in Eisenmenger
patients.
Background Pulmonary artery thrombosis is common in Eisenmenger syndrome, although its underlying pathophysiology is
poorly understood.
Methods Adult patients with Eisenmenger syndrome underwent computed tomography pulmonary angiography, cardiac
magnetic resonance imaging, and echocardiography. Measurement of ventricular function, pulmonary artery
size, and pulmonary artery blood flow were obtained. Hypercoagulability screening and platelet function assays
were performed.
Results Of 55 consecutive patients, 11 (20%) had a detectable thrombus. These patients were older (p  0.032), but did
not differ in oxygen saturation, hemoglobin, or hematocrit from those without thrombus. Right ventricular ejec-
tion fraction by magnetic resonance imaging was lower in those with thrombus (0.41  0.15 vs. 0.53  0.13,
p  0.017), as was left ventricular ejection fraction (0.48  0.12 vs. 0.60  0.09, p  0.002), a finding corrob-
orated by tissue Doppler and increased brain natriuretic peptide. Those with thrombus also had a larger main
pulmonary artery diameter (48  14 mm vs. 38  9 mm, p  0.007) and a lower peak systolic velocity in the
pulmonary artery (p  0.003). There were no differences in clotting factors, platelet function, or bronchial arter-
ies between groups. Logistic regression showed pulmonary artery velocity to be independently associated with
thrombosis.
Conclusions Pulmonary arterial thrombosis among adults with Eisenmenger syndrome is common and relates to older age,
biventricular dysfunction, and slow pulmonary artery blood flow rather than degree of cyanosis or coagulation
abnormalities. Further work to define treatment efficacy is needed. (J Am Coll Cardiol 2007;50:634–42)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.056w
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August 14, 2007:634–42 PA Thrombosis in Eisenmenger Syndromedvancement in our understanding of pathophysiology,
rognostic implications, or effectiveness of treatment.
The growing use of pulmonary angiography by computed
omography (CTPA) has renewed interest in this issue by
asily showing the lesions in vivo (5) with an overall
revalence of approximately 20% (6). Thrombi are report-
dly more common in women and in those with lower
xygen saturation, although no differences were shown in
emoglobin, platelet count, PA diameter, or right ventric-
lar dysfunction by echocardiography (6). Other studies
ave stirred interest in the potential relationship between
emoptysis and bronchial artery enlargement. Thus many
uestions remain unanswered, in particular the relationship
etween thrombosis and hemoptysis, because this has great
mplications for treatment.
This study investigated possible variables associated with
A thrombosis and hemoptysis in Eisenmenger patients to
etter understand the pathophysiological mechanisms and
ationale for treatment.
ethods
e designed a prospective cross-sectional study of consec-
tive adults with Eisenmenger physiology seen at the Royal
rompton Hospital. Portions of the study have been previ-
usly reported (7). The protocol was approved by the
nstitutional ethics committee, and all patients signed in-
ormed consent before participation. Patients with Down
yndrome or learning disabilities were eligible to participate,
nd were asked to sign consent together with their parent or
uardian.
atients. Eisenmenger syndrome was defined as all of the
ollowing: 1) known intracardiac or great artery shunt; 2)
ncreased PA pressure (tricuspid regurgitation velocity 4
/s or measured mean PA pressure 50 mm Hg); and 3)
eversed or bidirectional shunt resulting in hypoxemia (cu-
aneous oxygen saturation 92% at rest or 87% with
xercise). Patients with an atrial septal defect 3.0 cm and
o other shunt were not included (2). For patients with
ifferential cyanosis, eligibility was based on oxygen satura-
ion measured at the toe. Patients with impaired renal
unction (creatinine 1.5 mg/dl), pregnancy, or significant
omorbidity (decompensated heart failure, active hemopty-
is, recent surgery, or current infection) were excluded.
All studies were performed at the Royal Brompton
ospital within a 24-h period and according to accepted
linical standards. A complete history and physical exami-
ation were performed initially. Significant hemoptysis was
efined as any episode producing at least 1/4 cup of bright
ed blood. Oxygen saturation was measured in the finger or
oe after a minimum of 5 min rest in sitting position.
aturation also was measured after 5 min of supplemental
xygen via nonrebreather mask (15 l/min), and then again
n room air after 6 min of brisk walking. Distance walked in
min was also recorded (8). slood samples. A peripheral
enous catheter was inserted, and
lood samples were obtained for
easurement of full blood count,
lectrolytes, urate, and creati-
ine. Atrial natriuretic peptide
ANP) and brain natriuretic pep-
ide (BNP) were also measured
monoclonal antibody assay,
hionoria, Schering, West Sus-
ex, England). Viscosity and red
ell aggregation were measured
s previously described (7). After
ompletion of all investigations,
urther blood samples were drawn
or hypercoagulability screening.
he citrate concentration was ad-
usted based on packed cell volume
easured on the previous sample,
ollowing published guidelines (9).
omputed tomography. A
TPA scan was performed using
4-channel multidetector scan-
er (Somatom Volume Zoom;
iemens, Erlangen, Germany).
inety milliliters of contrast me-
ia (Ultravist 370, Schering, Ber-
in, Germany) were injected
hrough a peripheral venous
atheter via an automated injector (rate 4 ml/s). Because
enous-line air filters were incompatible with the rate of
njection, extra attention was made to eliminate air within
he line. Bolus tracking was done using built-in software
Carebolus, Siemens, Erlangen, Germany) to determine
omputed tomographic density of the main pulmonary
rtery (MPA) (or ascending aorta in cases with truncus
rteriosus). Scanning at held inspiration was begun when
ensity reached 100 HU.
Thrombi were identified from raw axial images by an
xperienced radiologist blinded to any other clinical infor-
ation. Diameter measurements of the MPA, right branch
ulmonary artery (RPA), and left branch pulmonary artery
LPA) within the mediastinum were made in the axial
lane. The largest bronchial arteries to the right and left
ungs were identified, and their diameters were measured.
agnetic resonance. Cardiovascular magnetic resonance
maging (CMR) was performed using a 1.5-T scanner
Sonata, Siemens, Erlangen, Germany) with a phased-array
ody coil. Steady-state free precession end-expiratory breath
old short-axis cine images (7 mm with 3-mm spacing)
ere obtained from base to apex. Through-plane phase
ontrast velocity mapping was made in the proximal MPA
nd proximal ascending aorta at held expiration. In patients
ith truncus arteriosus, in-plane flow through a cross
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
BNP  brain natriuretic
peptide
CI  confidence interval
CMR  cardiovascular
magnetic resonance
CTPA  computed
tomography pulmonary
angiogram
LPA  left pulmonary
artery
LV  left
ventricle/ventricular
MPA  main pulmonary
artery
OR  odds ratio
PA  pulmonary artery
RPA  right pulmonary
artery
RV  right
ventricle/ventricular
RVOT  right ventricular
outflow tract
VSD  ventricular septal
defectection of the RPA and LPA was used for pulmonary flow,
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PA Thrombosis in Eisenmenger Syndrome August 14, 2007:634–42nd aortic flow was measured distal to the origin of the PA
ranches.
Measurements of volume and flow were performed using
MR Tools software (Imperial College, London, En-
land). Right ventricular (RV) and left ventricular (LV)
olume at end diastole and end systole, indexed to body
urface area, were calculated using the Simpson method
ith careful contouring around each trabeculation and
utflow tracts as previously described (10). For patients with
ventricular septal defect (VSD), delineation between the
V and LV chambers at the defect was done using a line in
irect continuity with the septum. For each patient, the
iameter of the shunt was measured in 2 orthogonal planes,
nd these diameters were used to determine elliptical area.
he diameters of the MPA, RPA, and LPA were measured
rom axial single-phase spin echo images.
Phase contrast velocity flow maps of the MPA were used
o calculate maximum peak systolic velocity, mean systolic
elocity (average velocity of each pixel in the region of
nterest during systole), stroke volume, and flow. Mean and
aximum velocity were not determined for patients with
runcus arteriosus or aortopulmonary window. For determi-
ation of maximum velocity, care was taken to avoid
igh-shear areas near the perimeter of the region of interest.
chocardiography. Echocardiography was performed us-
ng a standard transthoracic approach with a Philips ultra-
ound imaging system (Sonos 7500, Hewlett-Packard, An-
over, Massachusetts) interfaced with a multifrequency
ransducer. Continuous-wave Doppler was aligned through
he right ventricular outflow tract (RVOT) to obtain a peak
elocity. Myocardial tissue Doppler velocities were recorded
sing spectral pulsed Doppler from the LV free wall,
eptum, and RV free wall from the apical four chamber
iew. All 2-dimensional images, Doppler flow velocities,
nd tissue Doppler velocities were recorded digitally with a
imultaneous electrocardiogram (lead II) and a phonocar-
iogram superimposed on each. EnConcert Echo Informa-
ion Management System (Philips, Reigate, England) was
sed to analyze the stored data.
oagulation and platelet function testing. Thrombo-
hilia assays were all performed on an automated analyzer
MDA-180 Biomerieux, Basingstoke, England) and in-
luded antithrombin activity, protein C activity (Bi-
merieux), and free protein S (Diagnostica Stago, Axis
hield, Huntingdon, England). von Willebrand antigen was
total antigen measurement using a latex particle assay
Diagnostica Stago, Axis Shield, Huntingdon, England).
latelet function assays were performed using the PFA-100
Sysmex, Milton Keynes, England), where closure time for
platelet plug to form as blood passes through an aperture
s measured in seconds.
tatistical analysis. Two groups were defined based on the
resence or absence of PA thrombus. Analysis was done
sing SPSS for Windows 11.0 (SPSS Inc., Chicago, Illi-
ois). Normality was tested using the Kolmogorov-Smirnov
ethod. Continuous variables were compared with Student wtest or the Mann-Whitney U test as appropriate. Cate-
orical variables were compared by chi-square or Fisher
xact test. Univariate regression was done using a Pearson
egression coefficient. To assess the uniqueness of associa-
ion between variables, logistic regression was performed on
ariables that were statistically different between groups,
ith no more than 3 variables included in any multivariate
odel at any time because of the limitations of sample size.
esults are expressed as mean  SD, or median/
nterquartile range for non-normal variables. A value of p 
.05 was considered statistically significant. No correction
as made for multiple tests.
esults
atients. Fifty-five patients were studied, 37 women and
8 men. Fifteen patients had Down syndrome or other
orms of developmental delay. Eleven patients (20%, 95%
onfidence interval [CI] 10% to 33%) had PA thrombus.
istribution of shunt types are shown (Table 1). Seven
atients had a systemic RV. For simplicity, this article will
se the term LV to mean the systemic ventricle and RV for
he pulmonic ventricle. Two patients had single-ventricle
hysiology (one with double-inlet LV, another with hypo-
lastic left heart/aortic atresia). Two had undergone pallia-
ive Mustard procedures without closure of the VSD. One
atient developed diffuse urticaria after CTPA, which
esolved completely after treatment. Another patient devel-
ped transient hand numbness immediately after the scan,
hich resolved in 30 min. There were no other adverse
vents.
General clinical characteristics of those with thrombus
ompared with those without are shown (Table 1). Those
ith thrombus were older (p  0.032), but did not differ
ith respect to gender or heart rate. We found no difference
n oxygen saturation at rest, after supplemental oxygen
91  5% vs. 91  7%), or after walking (60  8% vs. 58
9%) between patients with and without thrombus,
espectively. Six-minute walk distance was not different
339  62 m vs. 373  114 m). Similarly, there was no
ifference in hemoglobin, spun hematocrit, packed-cell
olume, transferrin saturation, or mean corpuscular volume
Table 1). Shunt area was not different between groups,
ven when analyzed separately according to shunt type.
A size. Pulmonary artery measurements from both com-
uted tomography and CMR are shown (Table 2). There
as excellent correlation between the 2 methods for mea-
urement of MPA, RPA, and LPA diameters (r  0.96,
.82, and 0.89 respectively; p  0.001 for each). Patients
ith thrombus had a significantly larger diameter of the
PA, RPA, and LPA. Because of an observed tendency for
referential dilatation of the RPA, the RPA/LPA diameter
atio was calculated for each patient and was found to be
ignificantly higher in those with thrombus than in those
ithout (Table 3).
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August 14, 2007:634–42 PA Thrombosis in Eisenmenger Syndromeentricular function. Forty-four patients (80%) were able
o undergo CMR scanning (10 patients with thrombus and
4 patients without). Reasons for not undergoing CMR
ncluded claustrophobia (n  3), presence of an implanted
acemaker (n  2), inability to comply with instructions
n  3), or scanner unavailability on the study day (n  3).
o significant differences were found between those who
id or did not participate in CMR.
Parameters of ventricular function measured by CMR
nd echocardiography are shown (Table 3). Mass index and
nd-diastolic volumes for RV and LV were not different
General Characteristics of Patients WithPulmonary Artery Thrombus Compared With Tho
Table 1 General Characteristics of PatientsPulmonary Artery Thrombus Compa
Shunt type
Atrial septal defect, n (%)
Ventricular septal defect, n (%)
Patent ductus arteriosus, n (%)
Atrioventricular septal defect, n (%)
Truncus or anteroposterior window, n (%)
Clinical
Age (yrs)
Female, n (%)
Developmental delay, n (%)
New York Heart Association functional class III or IV, n (%
History of hemoptysis, n (%)
Aspirin use currently, n (%)
Warfarin use currently, n (%)
Systemic right ventricle, n (%)
Heart rate (beats/min)
Oxygen saturation at rest (%)
Laboratory
Hemoglobin (g/dl)
Packed cell volume (%)
Mean corpuscular volume (fl)
Urate (mmol/l)
Serum albumin (g/dl)
C-reactive protein (mg/l)
Atrial natriuretic peptide (pmol/l)
Brain natriuretic peptide (pmol/l)
*p 0.028 for patent ductus versus atrial septal defect by Fisher exac
range).
Pulmonary Artery Diameters
Table 2 Pulmonary Artery Diameters
T
Computed tomography
Main pulmonary artery (mm) 4
Right pulmonary artery (mm) 3
Left pulmonary artery (mm) 3
Right/left pulmonary artery ratio 1.2
Pulmonary artery calcification present
Magnetic resonance
Main pulmonary artery (mm) 4
Right pulmonary artery (mm) 3
Left pulmonary artery (mm) 2Continuous variables are given as mean  SD or median (interquartile rangeetween patients with thrombus and without. However,
here was a significant difference in both RV and LV
jection fraction measured by CMR. Tissue Doppler peak
ystolic velocity of the LV free wall and septum were
ignificantly lower in those with thrombus versus those
ithout, although not different for the RV free wall. The
iastolic E=-wave velocity of the LV and RV free walls was
ower in those with thrombus versus those without, al-
hough not significantly different for the septum. Tissue
oppler A=-wave velocity was not different, nor was the
/E= ratio.
ithout
ith Those Without
hrombus (n  11) No Thrombus (n  44) p Value
2 (100%) 0
7 (23%) 24 (77%)
0 7 (100%) *
1 (11%) 8 (89%)
1 (17%) 5 (83%)
46.2  17.1 36.5  12 0.032
6 (55%) 31 (70%) NS
3 (27%) 12 (27%) NS
7 (64%) 14 (32%) NS
8 (73%) 19 (43%) 0.08
1 (9%) 13 (30%) NS
5 (45%) 8 (18%) NS
2 (18%) 5 (11%) NS
86  17 83  14 NS
81  6 81  8 NS
18.8  3.6 19.9  2.7 NS
57  10 61  8 NS
89  7 89  10 NS
372  111 413  118 NS
3.5  7.2 3.9  5 0.045
8 (16) 6 (6.8) NS
25 (40) 16 (20) NS
24 (43) 10 (15) 0.034
ontinuous variables are given as mean SD or median (interquartile
us No Thrombus p Value
4 38 9 0.007
25 (8) 0.001
25 7 0.006
.30 1.06 0.18 0.022
) 10 (23%) 0.002
34 (11) 0.016
21 (7) 0.002
) 19 (7) 0.006se W
With
red W
T
)hromb
8 1
7 (10)
3 9
2 0
8 (73%
2 (6)
8 (17)
9 (14).
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PA Thrombosis in Eisenmenger Syndrome August 14, 2007:634–42Both ANP and BNP levels were above the normal range
Table 1, normal values are 11 and 4 pmol/l, respec-
ively). There was a significantly higher BNP level in those
ith thrombus than without (Table 1), whereas ANP levels
id not differ.
ulmonary flow dynamics. Those with thrombus had a
ignificantly larger measured cross-sectional area of the
PA, as expected given the diameter differences described
Table 2). The maximum and mean peak systolic velocities
ere both significantly lower in those with thrombus than
hose without (Table 3). Stroke volume was not different.
y continuous-wave Doppler echocardiography, there was
o difference in peak velocity or velocity–time integral
Biventricular Function and Pulmonary Flow Dyna
Table 3 Biventricular Function and Pulmona
Magnetic resonance: volumes
RV end-diastolic volume index (ml/m2)
RV end-systolic volume index (ml/m2)
LV end-diastolic volume index (ml/m2)
LV end-systolic volume index (ml/m2)
RV mass index (g/m2)
LV mass index (g/m2)
RV ejection fraction
LV ejection fraction
Systemic blood flow (l/min)
Pulmonary blood flow (l/min)
Qp/Qs
Echocardiography: tissue Doppler
LV free wall peak systolic velocity (cm/s)
LV free wall peak E= wave velocity (cm/s)
Septal peak systolic velocity (cm/s)
Septal peak E=-wave velocity (cm/s)
RV free wall peak systolic velocity (cm/s)
RV free wall peak E=-wave velocity (cm/s)
Maximum peak systolic velocity (m/s)
Mean systolic velocity (m/s)
Main pulmonary artery cross-sectional area (cm2)
Pulmonary artery stroke volume (ml/beat)
Echocardiography: continuous-wave Doppler
RVOT peak velocity (m/s)
RVOT velocity time integral (cm)
RVOT diameter (cm)
RVOT area (cm2)
RVOT stroke volume (ml/beat)
Continuous variables are given as mean  SD or median (interquartil
LV  left venriuclar; RV  right ventricular; RVOT  right ventricula
oagulation Screening and Platelet Function Assays
Table 4 Coagulation Screening and Platelet Function Assays
Throm
Platelet count (109/l) 175
Platelet function assay (collagen/adenosine diphosphate) (s) 163
Platelet function assay (collagen/epinephrine) (s) 212
Antithrombin III (IU/dl) 81
Protein C (IU/dl) 83
Free protein S (%) 85von Willebrand factor (IU/dl) 163 91hrough the RVOT. Cross-sectional area of the RVOT
ased on measured diameter also was not different. There
as no difference in similar parameters for the LV outflow
ract or aorta using either echocardiography or CMR.
ypercoagulability screening and platelet function. Twenty-
ight patients were included in the hypercoagulability anal-
sis (Table 4). Patients were excluded because of warfarin or
spirin use, or inadequate blood samples (insufficient blood
olume, hemolysis, or clotted sample). There were no
ifferences in antithrombin III, protein C, free protein S, or
on Willebrand factor levels. There was no evidence of
upus anticoagulant in any patient. Homocysteine levels
ere within normal limits. Platelet function assays were
w Dynamics
Thrombus No Thrombus p Value
92 51 83 34 NS
57 47 41 24 NS
90 40 77 27 NS
50 34 32 15 0.029
64 22 66 26 NS
73 29 66 23 NS
0.41 0.15 0.53 0.13 0.017
0.48 0.12 0.60 0.09 0.002
4.96 1.26 4.82 1.43 NS
4.82 2.07 4.90 1.84 NS
0.95 0.27 1.09 0.80 NS
6.1 1.5 8.0 1.7 0.013
4.2 2.7 7.5 3.4 0.032
4.3 1.1 5.9 1.7 0.035
3.7 1.7 4.9 2.3 NS
7.8 1.8 10.8 15.3 NS
3.4 2.3 6.9 3.3 0.012
0.63 0.19 0.98 0.23 0.003
0.19 0.08 0.63 0.19 0.044
2.3 (19.1) 9.8 (4.6) 0.004
61 (40) 57 (37) NS
1.09 0.30 1.00 0.34 NS
4.42 7.29 14.85 6.40 NS
2.89 0.44 2.69 0.48 NS
6.7 2.0 5.9 2.1 NS
98 40 87 56 NS
).
w tract.
No Thrombus p Value Normal Range
139 59 0.071 150–400
200 70 NS 68–121
238 74 NS 85–140
88 16 NS 70–130
101 27 NS 70–130
113 20 NS 65–130mics
ry Flo
2
1bus
53
46
72
14
24
26168 55 NS 50–150
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August 14, 2007:634–42 PA Thrombosis in Eisenmenger Syndromeonsistently abnormal, with longer closure times in our
atients than the normal range, yet no differences were
ound between those with and without thrombus. There
as a nonsignificant trend toward higher platelet count in
hose with thrombus, however.
ronchial arteries and hemoptysis. Diameters of the right
nd left bronchial arteries were not different between those
ith and without thrombus (3.4  1.3 mm vs. 2.6  1.3
m and 2.9  1.0 mm vs. 2.5  1.2 mm for the right and
eft bronchial arteries, respectively). Bronchial artery diam-
ter did not correlate with pulmonary blood flow, oxygen
aturation, hemoglobin, or hematocrit. Although 78% of
atients with thrombus also reported prior significant he-
optysis, this did not reach statistical significance compared
ith those without thrombus (Table 1). There also was no
ifference in bronchial artery diameter in those with (n 
3) versus without (n  42) a history of significant
emoptysis.
ogistic regression. By logistic regression analysis, the
ariables with the strongest association with thrombus were
V ejection fraction (p  0.0065, odds ratio [OR] 0.89,
5% CI 0.82 to 0.97), age (p  0.04, OR 1.054, 95% CI
.01 to 1.087), and peak systolic PA velocity by CMR (p 
.013, OR 0.163, 95% CI 0.006 to 0.419). When these 3
ariables were compared in a multivariate model, peak
ystolic PA velocity was the only variable significantly
ssociated with thrombosis (p  0.034). The LV ejection
raction did not correlate with age or resting oxygen
aturation. In a model comparing only age and LV ejection
raction, LV ejection fraction was independently associated
ith thrombosis (p  0.007), whereas age was not.
iscussion
revalence. This prospective study confirms the relatively
igh prevalence (20%, 95% CI 10% to 33%) of PA throm-
us in Eisenmenger syndrome. In Wood’s classic series,
9% of patients died of massive hemoptysis, the cause of
hich “was usually pulmonary infarction from arterial
hrombosis” (2). Several retrospective studies concur (3,4).
erloff et al. (5) showed moderate to massive thrombi in
9% of 31 patients, and Silversides et al. (6) reported
hrombi in 21% of 34 patients.
In our study, thrombus formation was not dependent on
he severity of right-to-left shunt as measured by oxygen
aturation, degree of secondary erythrocytosis, or shunt area
easured by CMR. This was in contrast to the results of
ilversides et al. (6), who found lower resting oxygen
aturation in those with thrombus but no difference in
emoglobin or hematocrit. Others have shown that oxygen
aturation does not correlate with age or survival (11).
atients with thrombi in our study were older, also different
rom the findings of Silversides et al. (6), although the mean
ge for both study populations was not different. Because of
he potential relationship between age and ventricular func-
ion, we compared these in a logistic regression model andound that age was not uniquely associated with thrombus.
ilversides et al. (6) found more thrombi in women, whereas
e found no gender difference. No patients with thrombus
ere using oral contraception in the Toronto series (6) nor
n our own. Menstruating women may be more prone to
ron deficiency (7), although iron deficiency was not asso-
iated with thrombosis in our dataset.
echanism of thrombosis. Four possible etiologies of PA
hrombi in Eisenmenger syndrome can be hypothesized.
hrombi may arise from: 1) local vascular injury from
rogressive pulmonary hypertension; 2) hypercoagulability
econdary to cyanosis-related factor deficiencies or platelet
ysfunction; 3) sluggish flow in the pulmonary arteries
romoting red cell aggregation; or 4) embolic sources rather
han form in situ. We interpret the laminar position (12)
nd the successive layers of clot formation (Fig. 1) to
ndicate the later hypothesis is unlikely.
The first hypothesis is supported by the finding of
xtensive calcification in the pulmonary arteries (Fig. 2) in
hose with thrombus from both our data and the study by
ilversides et al. (6). We found no evidence of systemic
nflammation in those with thrombus as gauged by
-reactive protein (Table 1), although we did not study
ore specific markers of endothelial injury. Medial hyper-
rophy and intimal proliferation have been described in
isenmenger syndrome, with destruction of the elastica
nterna believed to be “the end result of trauma to the
ulmonary vessels from the elevated pulmonary pressure”
13). Based on such work, Wood (2) postulated that
hrombosis was secondary to atherosclerosis, although not
Figure 1 Cardiac MRI SSFP Image in Oblique Axial Plane
The patient has an aneurismal right pulmonary artery (RPA) with a laminar throm-
bus along its anterior wall (red arrow). Several different signal intensities within
the thrombus (yellow arrow) suggest successive laminar build-up in situ rather
than an embolic origin. MRI  magnetic resonance imaging; SSFP  steady state
free precession.
Please see the Appendix for accompanying video.
a
t
c
e
s
(
b
a
a
d
P
o
(
t
p
m
i
s
t
a
t
s
t
o
fl
i
B
t
d
(
f
t
t
p
p
a
T
p
e
c
a
a
c
B
p
t
t
f
i
c
p
s
p
640 Broberg et al. JACC Vol. 50, No. 7, 2007
PA Thrombosis in Eisenmenger Syndrome August 14, 2007:634–42ll agree (5). Overall, we find the theory that small intimal
earing contributes to local thrombogenesis very plausible.
We found no evidence of significant clotting factor deficien-
ies traditionally associated with hypercoagulability that could
xplain PA thrombosis. Deficiencies in clotting factors synthe-
ized by the liver have been shown in cyanotic heart disease
14,15) but without hypercoagulation. Such deficiencies may
e subclinical and unrelated to thrombosis (15).
Abnormal flow properties secondary to PA dilatation is
nother possible contributor to thrombogenesis. We found
highly significant difference in PA diameter, preferential
ilatation of the RPA compared with the LPA, and slower
A flow velocity in those with thrombus. Slow propagation
f pulsatile flow can be appreciated visually with CMR
Fig. 3, Online Video). Deceleration of fluid flowing
hrough a larger cross-sectional area is a well-understood
rinciple of fluid dynamics, and slow-moving blood pro-
otes the formation of aggregates. Red cell aggregation
ndex at low shear, which we measured and recently de-
cribed elsewhere (7), tended to be higher in those with
hrombus (13.03  2.52 vs. 10.92  2.41, p  0.059),
lthough not statistically significant. Thus, our interpreta-
ion of these findings is that patients with Eisenmenger
yndrome may be vulnerable to local thrombogenesis similar
o Fontan patients with right atrial enlargement. However,
ur data do not prove a cause-effect relationship between
ow and thrombosis, and it is also plausible that thrombus
s the primary cause of other abnormalities shown.
iventricular dysfunction. Biventricular systolic dysfunc-
ion is present in those with thrombi. Ventricular systolic
ysfunction may contribute to relative slowing of PA flow
Figure 2 Computed Tomographic Pulmonary Angiogram
This scan from a patient with a double-inlet left ventricle and large ventricular
septal defect shows extensive calcification of the left and right pulmonary arter-
ies (yellow arrows) with circumferential thrombi (red arrows). LPA  left pul-
monary artery; RPA  right pulmonary artery.Fig. 3). There was a weak correlation between LV ejectionraction and PA maximum velocity (r  0.33, p  0.08)
hat, although not statistically significant, adds credibility to
his theory, although again, a cause-effect relationship is not
roven. Both the RV and the LV contribute to PA flow in
atients with a VSD (including atrioventricular septal defect
nd truncus arteriosus), and face similar loading conditions.
hus an interventricular functional relationship is not sur-
rising. There was a strong correlation between RV and LV
jection fraction in this series (r  0.74, p  0.001), a
ommon phenomenon in congenital heart disease (16),
lthough not necessarily in other forms of pulmonary
rterial hypertension.
The BNP level is increased by 12 times the normal
oncentration in patients with cyanosis (17). The higher
NP level in those with thrombus in our series supports the
ossible pathogenic relationship between biventricular sys-
olic dysfunction and PA thrombus. The lower E= wave
issue Doppler velocity may indicate possible diastolic dys-
unction of the RV or LV, although we found no difference
n the E/E= ratio or mitral/tricuspid valve inflow patterns to
onfirm this. We found no difference in estimated PA
ressure by echocardiography between groups, which is not
urprising when considering the limitations of accuracy in
atients with pulmonary hypertension (18).
Figure 3 Cardiac MRI SSFP Image in Oblique Coronal Plane
The patient has a ventricular septal defect and severe biventricular dysfunc-
tion. The RPA is dilated and a large mural thrombus is present along its infe-
rior wall (red arrow). By cine imaging, sluggish flow in the pulmonary artery is
visible. MPA  main pulmonary artery; RV  right ventricle; other abbreviations
as in Figure 1.
Please see the Appendix for accompanying video.
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August 14, 2007:634–42 PA Thrombosis in Eisenmenger Syndromeronchial artery hypertrophy. We also hypothesized that
atients with prior hemoptysis would have larger bronchial
rteries, as has been shown in other congenital patients with
ulmonary vascular disease (19). This is the first study we
now of to investigate bronchial artery diameter critically in
isenmenger syndrome. Although the majority of our
atients had significant dilatation of the bronchial arteries
normal diameter is1.5 mm), we were unable to show any
ifference between those with or without hemoptysis, nor
etween those with or without thrombus, even after index-
ng for body size. Thus the role of the bronchial arteries in
he etiology of hemoptysis remains uncertain. Coil emboli-
ation of the bronchial arteries is sometimes considered as a
reatment approach for uncontrolled hemorrhage, although
sually as an empiric last resource (20).
linical implications. Although this study does not ad-
ress the efficacy of anticoagulation in prevention of either
hrombosis or hemoptysis, it does attempt to clarify the
elationship between these coexisting problems in Eisen-
enger patients. This is crucial for determining optimal
herapy, because treatment of one may worsen the other
12). Based on the belief that PA thrombi lead to microin-
arction, which then causes hemoptysis, Wood (2) believed
hat anticoagulation was warranted, which is supported by
ndings of fibrinoid necrosis in the PA (21). Since then,
owever, there have been virtually no clinical data published
o either validate or refute his recommendation.
Anticoagulation would likely be recommended by most
linicians today when thrombus is identified, although this
s not based on data (6), and legitimate arguments against
arfarin have been raised (5). Anticoagulation can provoke
ignificant hemoptysis (12), which occurs in 20% of patients
22) and is the cause of death in roughly 8% (2–4,23).
owever, a history of hemoptysis does not necessarily carry
rognostic weight (3,11,22,23). All available data are retro-
pective, with no standardization regarding how hemoptysis
s defined. Further, anticoagulation in cyanotic patients
equires citrate adjustment for accurate international nor-
alized ratio quantification (9), and improper monitoring
as lead to warfarin-related deaths in Eisenmenger syn-
rome (24). Finally, patients with idiopathic pulmonary
rterial hypertension are routinely anticoagulated, but are
istinctly different from Eisenmenger patients (2,23,25,26).
hus, empiric application of this same anticoagulation
trategy in patients with Eisenmenger syndrome may be
uestioned. Clearly, prospective data must be obtained for
his issue to be resolved.
tudy limitations. The sample size of our population
ave 80% power to show differences in the major findings
f PA size, LV ejection fraction, and peak systolic velocity
n the PA. Therefore a type I error is unlikely. Power to
void a type II error with hypercoagulability data is limited.
ased on the sample variation, our study was powered to
etect a 33% difference in protein C, which is typically
onsidered clinically deficient at 60% of normal. Thus it is
nlikely that smaller differences would be clinically relevant.e were not able to measure all potential factors that might
lay a role in thrombophilia. Our sample size did not allow
or comparison between shunt types. For example, 0 of the
patients with a patent ductus arteriosus had thrombi, but
oth patients with an atrial septal defect did. We cannot
onclude whether a physiological difference accounts for this
nding or whether this is attributable to chance. Because
his was designed as a cross-sectional study, the clinical
ndications for warfarin varied, and no conclusions regard-
ng warfarin efficacy can be made. None of the patients
sing warfarin were doing so because of previously detected
isks for hypercoagulation. There are additional important
uestions that our data do not answer, such as the patho-
enesis and timing of PA dilatation, the precise etiology of
iventricular dysfunction, and the cause-effect relationship
etween PA velocity and thrombosis. Larger studies may
hed additional light on the mechanisms of thrombosis and
emoptysis and on the potential effects of anticoagulation
herapy.
onclusions
n situ thrombosis in the PA of patients with Eisenmenger
yndrome is common and associated with older age, biven-
ricular dysfunction, dilatation of the pulmonary arteries,
nd concomitantly decreased pulmonary flow velocity. Nei-
her degree of cyanosis nor large differences in clotting
actors were associated with intrapulmonary thrombosis.
rospective data to establish the potential treatment effect of
nticoagulation in this patient group are greatly needed.
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